Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 10.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,432,697 shares of the company’s stock after acquiring an additional 136,458 shares during the period. Geode Capital Management LLC’s holdings in Day One Biopharmaceuticals were worth $19,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in DAWN. Renaissance Technologies LLC acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $994,000. Hsbc Holdings PLC purchased a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $163,000. Ally Bridge Group NY LLC purchased a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $7,387,000. Marshall Wace LLP boosted its holdings in Day One Biopharmaceuticals by 20.1% during the 2nd quarter. Marshall Wace LLP now owns 161,129 shares of the company’s stock valued at $2,220,000 after acquiring an additional 26,958 shares during the period. Finally, Point72 DIFC Ltd purchased a new stake in Day One Biopharmaceuticals during the second quarter worth about $124,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on DAWN. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN opened at $12.87 on Friday. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.94 and a 1 year high of $18.07. The company has a market capitalization of $1.30 billion, a PE ratio of -12.50 and a beta of -1.51. The company has a fifty day moving average of $13.86 and a two-hundred day moving average of $14.02.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the prior year, the firm posted ($0.54) EPS. On average, research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

Insider Activity

In related news, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the transaction, the insider now owns 1,057,535 shares of the company’s stock, valued at $17,026,313.50. This represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 51,745 shares of company stock valued at $748,567. Company insiders own 8.40% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.